Central to this initiative is the establishment of the Southwest Center for Advancing Clinical and Translational Innovation (SW CACTI), a flagship entity within the NIH Clinical and Translational Science Award (CTSA) program. The CTSA consortium is a network of 61 leading academic health centers nationwide, all focused on enhancing translational science—the process that bridges laboratory research and clinical application. SW CACTI represents a strategic convergence of expertise and resources from two prominent institutions, harnessing their clinical strengths and research capacities to create an integrated platform dedicated to rapid innovation and community-focused health solutions across the Southwest.

The seven-year, $43.6 million funding package is comprised of approximately $38.8 million allocated to foundational translational science research, supplemented by a $4.8 million K12 Research Training and Career Development Award. This supplementary funding is designed to empower aspiring translational scientists through rigorous training and mentorship opportunities. The overarching goal is to foster a dynamic workforce capable of advancing the field of translational medicine by integrating clinical insights and cutting-edge research methodologies, ensuring that biomedical discoveries more swiftly permeate clinical practice and community health interventions.

Dr. Sally Radovick, who leads SW CACTI at the University of Arizona, emphasizes the critical role of this partnership in addressing the unique demographic and epidemiological characteristics shared by Arizona and New Mexico. Both states have large Native American and rural populations, presenting challenges in healthcare access and delivery that necessitate tailored solutions supported by robust clinical research infrastructure. By expanding the reach and capabilities of the CTSA network in the region, SW CACTI will enhance clinical trial enrollment and broaden the availability of therapeutic advances to underserved populations, thus promoting health equity.

Banner Health, the University of Arizona’s primary clinical partner, is poised to play an integral role in the implementation of SW CACTI’s research agenda. According to Dr. Corey Casper, chief research officer at Banner Health, the CTSA award will accelerate the health system’s ability to conduct pioneering clinical research, facilitate rapid translation of innovations into patient care, and nurture a community-engaged research culture. This partnership will not only increase clinical research capacity but also help develop a robust pipeline of clinician-scientists trained to tackle complex health problems within diverse patient populations.

Collaborative efforts extend beyond these core institutions, encompassing regional partners such as Arizona State University, Northern Arizona University, Mayo Clinic, Phoenix Children’s Hospital, Diné College, and several health organizations including the Flinn Foundation and the Arizona Department of Health Services. This collective network represents a multi-disciplinary ecosystem fostering translational science through shared expertise, data resources, and community engagement. The integration of academic, clinical, and public health stakeholders is foundational to SW CACTI’s strategy to translate research findings quickly into actionable healthcare solutions.

The SW CACTI initiative has identified substance use disorders and rural health disparities as focal points for translational research. Notably, both Arizona and New Mexico are grappling with an ongoing opioid crisis that disproportionately affects rural communities. SW CACTI’s translational research approach aims to develop and disseminate innovative opioid addiction treatment strategies tailored to rural healthcare settings. This includes expanding access to medications, behavioral interventions, and specialized clinical services to enhance outcomes for patients suffering from opioid use disorder.

A key translational research project spearheaded by the team will evaluate the deployment of a new addiction consult service at the University of New Mexico Hospital. Led by Dr. Nancy Pandhi, the investigation centers on assessing whether this model increases outpatient follow-up care for patients with opioid use disorder after hospital discharge. The insights garnered will be compared with similar services implemented in rural hospitals, thereby generating evidence to refine addiction treatment protocols and delivery systems across rural and urban settings alike.

Beyond targeted studies, SW CACTI will support a competitive pilot funding mechanism to stimulate innovative translational research projects. Researchers from both the University of Arizona and the University of New Mexico will have the opportunity to apply for these funds, promoting cross-institutional collaboration as well as independent investigations. This approach not only encourages scientific diversity and novelty but also fosters a collaborative research culture, leveraging the complementary strengths of both institutions.

Integral to the SW CACTI mission is the training and professional development of early-career scientists specializing in translational research. The K12 Research Training and Career Development Award will enable systematic mentorship and skill-building programs, ensuring a sustainable pipeline of investigators proficient in bridging basic science and clinical applications. Community engagement and inclusivity remain pivotal, with efforts to expand undergraduate programs designed to inspire students from diverse backgrounds, thereby diversifying the translational science workforce of the future.

Monitoring and evaluation represent critical components of SW CACTI’s framework, with plans to track outcomes across economic, policy, clinical, and public health domains. These metrics will provide comprehensive insights into the initiative’s impact in transforming healthcare delivery, research innovation, and workforce development across the Southwest. The ability to quantitatively assess the program’s success will inform iterative improvements and serve as a model for similar programs nationwide.

This grant award underscores a strategic vision by the NIH and its CTSA program to leverage regional strengths and collaborations for high-impact translational science. By addressing region-specific health challenges through cutting-edge clinical research, training, and community partnerships, SW CACTI partners aim to accelerate innovative healthcare solutions that are both scientifically rigorous and deeply attuned to the needs of diverse populations in Arizona and New Mexico.

Subject of Research: Translational Science and Clinical Research in Healthcare, Substance Use Disorders, Rural Health Initiatives
Article Title: University of Arizona and University of New Mexico Launch Southwest Translational Science Initiative with $43.6 Million Federal Grant
News Publication Date: Not explicitly provided
Web References: NIH National Center for Advancing Translational Sciences (NCATS) UM1TR005466 grant information
Image Credits: Photo by Kris Hanning, U of A Office of Research and Partnerships
Keywords: Rural populations, Substance abuse, Opioid addiction, Clinical studies, Health care

Dr. Sharma’s impressive credentials include a distinguished tenure at the HonorHealth Research Institute, where he has been a pivotal force since 2017. His expertise encompasses research design, drug development, and clinical trial methodology, which have set new benchmarks in the field. Now, as Chief of Translational Research and Drug Discovery, Dr. Sharma will leverage his knowledge and leadership skills to spearhead initiatives that convert basic scientific discoveries into actionable cancer therapies, thereby bridging the gap between laboratory research and clinical application.

Under his guidance, a multidisciplinary team comprising scientists, researchers, chemists, and clinical personnel will work collaboratively to bring forth breakthrough therapies that harness cutting-edge science to improve the quality of life for cancer patients. This initiative reflects a broader trend in oncology aimed at integrating scientific discovery with patient care, fostering an environment where innovation thrives and patient outcomes are continually optimized.

Mark Slater, Ph.D., Vice President of Research at HonorHealth, expressed confidence in Dr. Sharma’s abilities, stating that he is uniquely qualified to lead this ambitious venture. Dr. Slater remarked on Dr. Sharma’s diverse skill set, noting his blend of scientific acumen, clinical expertise, and innovative thinking. As the institute seeks to elevate its research capabilities, Dr. Sharma’s role will be integral in developing educational programs and collaborations that will further enhance the institute’s reputation in the field.

This new leadership position is not only a testament to Dr. Sharma’s remarkable career but also aligns with HonorHealth Research Institute’s strategic partnership with Arizona State University’s School of Medicine and Advanced Medical Engineering. It signifies a groundbreaking initiative to combine academic research with clinical practice, allowing for a seamless transfer of knowledge and technology that amplifies the impact of research on patient care.

Dr. Sharma’s career is marked by his dedication to drug discovery and innovation. He has made substantial contributions to the field of cancer treatment by developing novel therapeutic approaches, particularly in the area of immunotherapy. His groundbreaking work has notably expanded beyond gastrointestinal cancers to address pressing health challenges such as COVID-19 and Alzheimer’s disease, illustrating his commitment to advancing medicine across multiple fronts.

As part of his expanded role, Dr. Sharma has also been appointed to the Virginia G. Piper Distinguished Chair in Innovative Cancer Research, previously held by renowned pancreatic cancer specialist Daniel D. Von Hoff, M.D. This position carries with it an endowment that will fund Dr. Sharma’s pioneering cancer research and clinical trials, ensuring that his initiatives will have the financial backing necessary to achieve meaningful, impactful results.

Dr. Sharma’s future endeavors will focus on harnessing the power of translational medicine, which seeks to expedite the application of laboratory findings to clinical environments. His vision for the Center for Translational Science emphasizes the importance of innovation in treatment modalities, aiming to develop therapies that not only address the disease’s biological underpinnings but also consider patient-centered approaches that improve overall well-being.

The breadth of Dr. Sharma’s experience includes key leadership roles at notable institutions like the Huntsman Cancer Institute and the Translational Genomics Research Institute (TGen), where he significantly advanced clinical research programs. His ability to foster collaborations with pharmaceutical companies enables him to bridge the gap between emerging scientific discoveries and tangible treatment options.

Among his notable achievements, Dr. Sharma has played a crucial role in developing targeted therapies such as ceritinib, pembrolizumab, and nivolumab, which have proven essential in the fight against various cancers, including lung cancer and melanoma. These therapeutic agents exemplify a new era in oncology where personalized medicine is paramount, allowing for tailored treatment strategies that maximize therapeutic efficacy while minimizing adverse effects.

His academic contributions are equally impressive, serving as a professor of medical oncology and mentoring numerous aspiring researchers and practitioners. Dr. Sharma’s profound impact on the field is not only evident in his clinical and research roles but also through his dedication to education and mentorship, nurturing the next generation of cancer researchers and clinicians who will continue the fight against this formidable disease.

Dr. Sharma’s commitment to advancing cancer research is rooted in a genuine desire to improve patient outcomes and quality of life. Throughout his career, he has maintained a clear focus on innovation and has consistently sought to explore new frontiers in treatment options deliberately. His appointment at the HonorHealth Research Institute signifies a renewed commitment to research excellence and patient care, ensuring that cutting-edge therapies are accessible to those in need.

As Dr. Sharma embarks on this new chapter at HonorHealth, the future looks promising for patients and researchers alike. His leadership will undoubtedly yield transformative results as the Center for Translational Science works diligently to pioneer breakthroughs in cancer care, ultimately striving to provide patients with access to the most advanced treatments available.

The HonorHealth Research Institute stands at the forefront of transformative cancer research, and with Dr. Sunil Sharma at the helm of the Center for Translational Science, the possibilities for innovative cancer therapies are limitless. This new era in cancer treatment is not only about scientific advancements but also about the unyielding spirit of compassion that Dr. Sharma embodies, aligning his journey with the broader goal of alleviating the burdens that cancer places on patients and their families.

With his extensive background, collaborative spirit, and unwavering commitment to scientific innovation, Dr. Sharma is primed to lead HonorHealth Research Institute into a future filled with promise and potential as they collectively tackle the complexities of cancer and work towards a world where cancer is no longer a death sentence, but a manageable condition.

By embracing the synergy of research, academic collaboration, and clinical expertise, HonorHealth Research Institute aims to usher in a new paradigm of care that prioritizes the patient experience while advancing the field of oncology.

Subject of Research: Translational research for cancer therapeutics
Article Title: HonorHealth Research Institute Welcomes Leading Expert in Anti-Cancer Drug Development as Director of New Center for Translational Science
News Publication Date: February 18, 2025
Web References: HonorHealth Research Institute
References: None
Image Credits: Credit: Courtesy of HonorHealth Research Institute
Keywords: Anti-cancer drugs, translational research, drug discovery, immunotherapy, cancer therapeutics, HonorHealth, Arizona State University